Nicotine/mecamylamine-transdermal - Elan
Latest Information Update: 02 Aug 2002
At a glance
- Originator Elan Corporation
- Mechanism of Action Nicotinic receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Smoking withdrawal
Most Recent Events
- 23 Jun 1999 New profile
- 23 Jun 1999 Phase-III clinical trials for Smoking withdrawal in USA (Transdermal)